Scholarlink

<p>Therapy resistance in breast cancer is increasingly understood as a dynamic state transition driven by inflammatory survival signaling, phenotypic plasticity, and treatment-induced adaptive rewiring rather than as a single endpoint event. Although anthocyanins and anthocyanidins are widely discussed as anticancer phytochemicals, their relevance to the therapy resistance depends on their capacity to modify defined therapy-resistant states under pharmacologically meaningful conditions. Contextually, this article critically evaluates the preclinical evidence and proposes the 3PM-guided conceptual innovation for anthocyanin- and anthocyanidin-linked drug sensitization in therapy-resistant breast cancers, using specifically the NF-κB/EMT crosstalk as a functional lens. To this end, NF-κB/EMT signaling as the proposed target, per strong scientific evidence, is involved in pathways considered central for the phenotype-specific epigenetic regulation of health risks, malignant transformation, development of metastatic disease and therapy resistance. Finally, patient phenotyping and stratification, targeted risk mitigation and treatments tailored to individualized patient profiles are considered essential pillars for improved individual outcomes in the 3PM-guided paradigm.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adjuvant therapies by anthocyanins potentially mitigating drug resistance and metastatic disease risks in stratified breast cancers: the 3PM-conceptual innovation targeted to NF-kappaB/EMT plasticity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月13日

查看全文
  • Anita Sventekova,
  • Peter Kubatka,
  • Iva Slaninova,
  • Daniela Nykodymova,
  • Lubica Hornakova,
  • Alexandra Trbolova,
  • Vadim Goncharenko,
  • Karel Smejkal,
  • Olga Golubnitschaja

摘要

Therapy resistance in breast cancer is increasingly understood as a dynamic state transition driven by inflammatory survival signaling, phenotypic plasticity, and treatment-induced adaptive rewiring rather than as a single endpoint event. Although anthocyanins and anthocyanidins are widely discussed as anticancer phytochemicals, their relevance to the therapy resistance depends on their capacity to modify defined therapy-resistant states under pharmacologically meaningful conditions. Contextually, this article critically evaluates the preclinical evidence and proposes the 3PM-guided conceptual innovation for anthocyanin- and anthocyanidin-linked drug sensitization in therapy-resistant breast cancers, using specifically the NF-κB/EMT crosstalk as a functional lens. To this end, NF-κB/EMT signaling as the proposed target, per strong scientific evidence, is involved in pathways considered central for the phenotype-specific epigenetic regulation of health risks, malignant transformation, development of metastatic disease and therapy resistance. Finally, patient phenotyping and stratification, targeted risk mitigation and treatments tailored to individualized patient profiles are considered essential pillars for improved individual outcomes in the 3PM-guided paradigm.

Graphical Abstract